Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Controlled Contamination Services Awarded ISO 9001:2015 Certification

For over 25 years, CCS has provided facility cleaning solutions, technical services and decontamination service to millions of square feet of sensitive client spaces throughout the United States. CCS tailors its solutions with proven best practices in facility services and cleaning controlled environments. To do so, we develop the optimal cleaning strategy for each situation by assembling the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

For over 25 years, CCS has provided facility cleaning solutions, technical services and decontamination service to millions of square feet of sensitive client spaces throughout the United States. CCS tailors its solutions with proven best practices in facility services and cleaning controlled environments. To do so, we develop the optimal cleaning strategy for each situation by assembling the right resources, processes, and expert personnel to ensure the integrity of your environments.

Our Commitment to Providing the Highest Quality Services

Controlled Contamination Services’ certification to the 9001 Standard demonstrates our commitment to providing the highest quality services to our clients. As a US-based provider of enterprise solutions for the pharmaceutical, biotech, medical device, High Tech, IT, and Aerospace and Defense industries, CCS provides its clients with comprehensive cleaning, bio-decontamination, and technical service solutions that exceed the health, safety and environmental requirements of its customers.

Meeting the International Standard for a Quality Management System

The ISO 9001 standard is the international standard that specifies requirements for a quality management system (QMS). Organizations use the standard to demonstrate the ability to consistently provide products and services that meet customer and regulatory requirements. It is the ultimate global benchmark for quality management—a critical tool for both CCS and the partnerships it creates with its customers.

Continuous improvement and High-Quality Service Delivery are fundamental values at CCS. CCS’ clients require detailed and accurate documentation as well as adherence to Good Manufacturing Practices and Good Documentation Practices. CCS works under some of the most rigorous procedures as specified by the FDA and other US regulatory agencies and has a long history of developing and improving procedures and processes as well as developing and maintaining these requirements for their clients.

Streamlining Efficiency to Contain Cost and Reduce Clients’ Total Spend

The ISO certification also provides CCS the opportunity to streamline efficiency, contain cost and total spend to its clients. In addition, it allows CCS the ability to continuously improve its consistency and information flow, time management, service delivery and service performance, customer service, accountability and tracking of key performance measurements, to the highest level possible.

CCS is the leading provider of integrated facility services for the Life Sciences, High Tech, IT, and Aerospace and Defense industries. One of our highest values as a company is quality and rigorous dedication to the needs of each of our unique clients. To learn more, please visit cleanroomcleaning.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512